Literature DB >> 25512166

Interferon-γ in foam cell formation and progression of atherosclerosis.

Xiao-Hua Yu1, Jian Zhang2, Xi-Long Zheng3, Yun-Hua Yang4, Chao-Ke Tang5.   

Abstract

Interferon-γ (IFN-γ), the sole member in type II IFN predominantly secreted by macrophages and T cells, is a critical regulator of immune function and provides a robust first line of defense against invading pathogens. Binding of IFN-γ to its receptor complex can activate a variety of downstream signaling pathways, particularly the Janus kinase (JAK)/signal transducer and activator of transcription (STAT), to induce gene transcription within the target cells. This pro-inflammatory mediator is highly expressed in atherosclerotic lesions and promotes foam cell formation, but its effects on the atherogenesis are complex, with both pro- and anti-atherogenic properties. IFN-γ also contributes to the development of myocardial infarction and stroke, the two main atherosclerotic diseases. Inhibition of IFN-γ signaling may prevent the development of atherosclerosis and help treat atherosclerotic diseases. Since IFN-γ may also exert anti-atherogenic effects, the safety and efficacy of anti-IFN-γ treatment still require careful evaluation in the clinical setting. In the current review, we summarize recent progression on regulation and signaling pathways of IFN-γ, and highlight its roles in foam cell formation, atherosclerosis, myocardial infarction as well as stroke. An increased understanding of these processes will help to develop novel IFN-γ-centered therapies for atherosclerotic diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Foam cells; IFN-γ; Myocardial infarction; Stroke

Mesh:

Substances:

Year:  2014        PMID: 25512166     DOI: 10.1016/j.cca.2014.12.007

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Authors:  S Pérez-Baos; J I Barrasa; P Gratal; A Larrañaga-Vera; I Prieto-Potin; G Herrero-Beaumont; R Largo
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

Review 2.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

3.  Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study.

Authors:  Jiayi Zhang; Yanfen Cui; Kaikai Wei; Zhenhui Li; Dandan Li; Ruirui Song; Jialiang Ren; Xin Gao; Xiaotang Yang
Journal:  Gastric Cancer       Date:  2022-08-06       Impact factor: 7.701

4.  Anti-Inflammatory Potential of Fucoidan for Atherosclerosis: In Silico and In Vitro Studies in THP-1 Cells.

Authors:  Etimad Huwait; Dalal A Al-Saedi; Zeenat Mirza
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

Review 5.  IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Xiaojie He
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 6.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

7.  Macrophage Foam Cell-Targeting Immunization Attenuates Atherosclerosis.

Authors:  Fazhan Wang; Zhi Zhang; Aiping Fang; Quansheng Jin; Dailong Fang; Yongmei Liu; Jinhui Wu; Xiaoyue Tan; Yuquan Wei; Chunling Jiang; Xiangrong Song
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.